First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Karim AmraneMargaux GeierRomain CorreHervé LénaGuillaume LéveillerFlorence GadbyRégine LamyJean-Louis BizecEric GoarantGilles RobinetSylvie GouvaGilles QuereRonan AbgralUlrike SchickCyril BernierChristos ChouaidRenaud DescourtPublished in: Cancer medicine (2020)
In a real-life cohort of advanced NSCLC patients (including PS 2 and untreated brain metastases), with PD-L1 TPS ≥50%, pembrolizumab demonstrates similar PFS to the pivotal clinical trial.